GNPNAT1 promotes the stemness of breast cancer and serves as a potential prognostic biomarker

Hu,Hao; Hu,Hao; Hu,Hao; Hu,Hao; Hu,Hao; Wang,Zhi-Wen; Wang,Zhi-Wen; Wang,Zhi-Wen; Wang,Zhi-Wen; Wang,Zhi-Wen; Hu,Shuang; Hu,Shuang; Hu,Shuang; Hu,Shuang; Hu,Shuang; Xiang,Yuan; Xiang,Yuan; Xiang,Yuan; Xiang,Yuan; Xiang,Yuan; Deng,Yang; Deng,Yang; Deng,Yang; Deng,Yang; Deng,Yang; Wan,Fu-Jian; Wan,Fu-Jian; Wan,Fu-Jian; Wan,Fu-Jian; Wan,Fu-Jian; Zhang,Tong-Cun; Zhang,Tong-Cun; Zhang,Tong-Cun; Zhang,Tong-Cun; Zhang,Tong-Cun; Yang,Zhong-Yi; Yang,Zhong-Yi; Yang,Zhong-Yi; Yang,Zhong-Yi; Yang,Zhong-Yi; Liao,Xing-Hua; Liao,Xing-Hua; Liao,Xing-Hua; Liao,Xing-Hua; Liao,Xing-Hua

doi:10.3892/or.2023.8594

GNPNAT1 promotes the stemness of breast cancer and serves as a potential prognostic biomarker

Authors:
- Hao Hu
- Zhi-Wen Wang
- Shuang Hu
- Yuan Xiang
- Yang Deng
- Fu-Jian Wan
- Tong-Cun Zhang
- Zhong-Yi Yang
- Xing-Hua Liao
View Affiliations

Affiliations: College of Life and Health Sciences, Institute of Biology and Medicine, Wuhan University of Science and Technology, Wuhan, Hubei 430000, P.R. China, Yueyang People's Hospital, Yueyang Hospital Affiliated to Hunan Normal University, Yueyang Breast Disease Diagnosis and Treatment Technology Research Center, Yueyang, Hunan 414000, P.R. China, Department of Medical Laboratory, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China
Published online on: June 28, 2023 https://doi.org/10.3892/or.2023.8594
Article Number: 157
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucosamine‑phosphate N‑acetyltransferase 1 (GNPNAT1) is a member of the acetyltransferase superfamily, related to general control non‑depressible 5 (GCN5). It has been documented that GNPNAT1 expression is increased in lung cancer, whereas its involvement in breast cancer (BC) remains to be further investigated. The present study aimed to evaluate the expression levels of GNPNAT1 in BC and its effect on BC stem cells (BCSCs). The Cancer Genome Atlas (TCGA) database was used for the analysis of the expression of GNPNAT1 and its clinical significance. Cox regression and logistic regression analyses were used to evaluate prognosis‑related factors. The GNPNAT1‑binding protein network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) application. The biological signaling pathways implicated in GNPNAT1 were investigated through function enrichment analysis including Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and gene set enrichment analysis. The single‑sample GSEA method was used to investigate the connection between the level of immune infiltration and GNPNAT1 expression in BC. GNPNAT1 expression was upregulated in patients with BC and was significantly associated with a poor prognosis. GNPNAT1 and its co‑expressed genes were mostly enriched in nuclear transport, Golgi vesicle transport, ubiquitin‑like protein transferase activity and ribonucleoprotein complex binding, as determined using functional enrichment analysis. GNPNAT1 expression was positively associated with Th2 cells and T‑helper cells, and negatively associated with plasmacytoid dendritic cells, CD8⁺ T‑cells and cytotoxic cells. Additionally, the GNPNAT1 expression levels were considerably increased in BCSCs. GNPNAT1 knockdown markedly decreased the stemness ability of SKBR3 and Hs578T cells, including the production of CSC markers and mammosphere or clone formation, while GNPNAT1 overexpression increased the stemness level. Hence, the findings of the present study demonstrate that GNPNAT1 may be exploited as a novel prognostic biomarker and therapeutic target for BC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Zhu J, Wu G, Zhao Y, Yang B, Chen Q, Jiang J, Meng Y, Ji S and Gu K: Epidemiology, treatment and prognosis analysis of small cell breast carcinoma: A population-based study. Front Endocrinol (Lausanne). 13:8023392022. View Article : Google Scholar : PubMed/NCBI
3	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
4	Duffy MJ, Walsh S, McDermott EW and Crown J: Biomarkers in breast cancer: Where are we and where are we going? Adv Clin Chem. 71:1–23. 2015. View Article : Google Scholar : PubMed/NCBI
5	Bao Z, Cheng J, Zhu J, Ji S, Gu K, Zhao Y, Yu S and Meng Y: Using weighted gene co-expression network analysis to identify increased MND1 expression as a predictor of poor breast cancer survival. Int J Gen Med. 15:4959–4974. 2022. View Article : Google Scholar : PubMed/NCBI
6	Deng M, Xiong C, He ZK, Bin Q, Song JZ, Li W and Qin J: MCTS1 as a novel prognostic biomarker and its correlation with immune infiltrates in breast cancer. Front Genet. 13:8259012022. View Article : Google Scholar : PubMed/NCBI
7	Rajarajan D, Kaur B, Penta D, Natesh J and Meeran SM: miR-145-5p as a predictive biomarker for breast cancer stemness by computational clinical investigation. Comput Biol Med. 135:1046012021. View Article : Google Scholar : PubMed/NCBI
8	Elhossini RM, Ahmed HA, Otaify G, Ghorab RM, Amr K and Aglan M: A novel variant in GNPNAT1 gene causing a spondylo-epi-metaphyseal dysplasia resembling PGM3-Desbuquois like dysplasia. Am J Med Genet A. 188:2861–2868. 2022. View Article : Google Scholar : PubMed/NCBI
9	Sabbagh Q, Alkar F, Patte K, Prodhomme O, Janel C, Touraine R, Jeandel C and Geneviève D: A second individual with rhizomelic spondyloepimetaphyseal dysplasia and homozygous variant in GNPNAT1. Eur J Med Genet. 65:1044952022. View Article : Google Scholar : PubMed/NCBI
10	Ain NU, Baroncelli M, Costantini A, Ishaq T, Taylan F, Nilsson O, Mäkitie O and Naz S: Novel form of rhizomelic skeletal dysplasia associated with a homozygous variant in GNPNAT1. J Med Genet. 58:351–356. 2021. View Article : Google Scholar : PubMed/NCBI
11	Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, et al: Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 7:116122016. View Article : Google Scholar : PubMed/NCBI
12	Bacos K, Gillberg L, Volkov P, Olsson AH, Hansen T, Pedersen O, Gjesing AP, Eiberg H, Tuomi T, Almgren P, et al: Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes. Nat Commun. 7:110892016. View Article : Google Scholar : PubMed/NCBI
13	Zhao M, Li H, Ma Y, Gong H, Yang S, Fang Q and Hu Z: Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1). Int J Nanomedicine. 12:1685–1697. 2017. View Article : Google Scholar : PubMed/NCBI
14	Zheng X, Li Y, Ma C, Zhang J, Zhang Y, Fu Z and Luo H: Independent prognostic potential of GNPNAT1 in lung adenocarcinoma. Biomed Res Int. 2020:88514372020. View Article : Google Scholar : PubMed/NCBI
15	Zhang S, Zhang H, Li H, Guo J, Wang J and Zhang L: Potential role of glucosamine-phosphate N-acetyltransferase 1 in the development of lung adenocarcinoma. Aging (Albany NY). 13:7430–7453. 2021. View Article : Google Scholar : PubMed/NCBI
16	Zhu P, Gu S, Huang H, Zhong C, Liu Z, Zhang X, Wang W, Xie S, Wu K, Lu T and Zhou Y: Upregulation of glucosamine-phosphate N-acetyltransferase 1 is a promising diagnostic and predictive indicator for poor survival in patients with lung adenocarcinoma. Oncol Lett. 21:4882021. View Article : Google Scholar : PubMed/NCBI
17	Liu W, Jiang K, Wang J, Mei T, Zhao M and Huang D: Upregulation of GNPNAT1 predicts poor prognosis and correlates with immune infiltration in lung adenocarcinoma. Front Mol Biosci. 8:6057542021. View Article : Google Scholar : PubMed/NCBI
18	Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C and Lander ES: Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 146:633–644. 2011. View Article : Google Scholar : PubMed/NCBI
19	Kreso A and Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell. 14:275–291. 2014. View Article : Google Scholar : PubMed/NCBI
20	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
21	Charafe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti P, Josselin E, Adelaide J, Nguyen TT, Monville F, et al: ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 73:7290–7300. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, et al: UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 25:18–27. 2022. View Article : Google Scholar : PubMed/NCBI
23	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Chen F, Chandrashekar DS, Varambally S and Creighton CJ: Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat Commun. 13:26692022. View Article : Google Scholar : PubMed/NCBI
25	Chen F, Chandrashekar DS, Varambally S and Creighton CJ: Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 10:56792019. View Article : Google Scholar : PubMed/NCBI
26	Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
27	Vasaikar SV, Straub P, Wang J and Zhang B: LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 46((D1)): D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
28	Wang J, Vasaikar S, Shi Z, Greer M and Zhang B: WebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res. 45((W1)): W130–W137. 2017. View Article : Google Scholar : PubMed/NCBI
29	Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An integrated repository portal for tumor-immune system interactions. Bioinformatics. 35:4200–4202. 2019. View Article : Google Scholar : PubMed/NCBI
30	Park SY: Nomogram: An analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 155:17932018. View Article : Google Scholar : PubMed/NCBI
31	Hu H, Xiang Y, Zhang XY, Deng Y, Wan FJ, Huang Y, Liao XH and Zhang TC: CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker. Oncol Rep. 48:1722022. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
33	Ai L, Mu S, Sun C, Fan F, Yan H, Qin Y, Cui G, Wang Y, Guo T, Mei H, et al: Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Mol Cancer. 18:882019. View Article : Google Scholar : PubMed/NCBI
34	Ma XL, Hu B, Tang WG, Xie SH, Ren N, Guo L and Lu RQ: CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol. 13:112020. View Article : Google Scholar : PubMed/NCBI
35	Aquino-Gil M, Pierce A, Perez-Cervera Y, Zenteno E and Lefebvre T: OGT: A short overview of an enzyme standing out from usual glycosyltransferases. Biochem Soc Trans. 45:365–370. 2017. View Article : Google Scholar : PubMed/NCBI
36	Furuta E, Okuda H, Kobayashi A and Watabe K: Metabolic genes in cancer: Their roles in tumor progression and clinical implications. Biochim Biophys Acta. 1805:141–152. 2010.PubMed/NCBI
37	Olivier-Van Stichelen S, Drougat L, Dehennaut V, El Yazidi-Belkoura I, Guinez C, Mir AM, Michalski JC, Vercoutter-Edouart AS and Lefebvre T: Serum-stimulated cell cycle entry promotes ncOGT synthesis required for cyclin D expression. Oncogenesis. 1:e362012. View Article : Google Scholar : PubMed/NCBI
38	Usui T, Sakurai M, Enjoji S, Kawasaki H, Umata K, Ohama T, Fujiwara N, Yabe R, Tsuji S, Yamawaki H, et al: Establishment of a novel model for anticancer drug resistance in three-dimensional primary culture of tumor microenvironment. Stem Cells Int. 2016:70538722016. View Article : Google Scholar : PubMed/NCBI